AbbVie Soars 3.66% on Q1 Earnings Beat

AbbVie's stock rose 3.66% in pre-market trading on April 25, 2025, driven by strong first-quarter financial results.

AbbVie reported first-quarter 2025 revenue of $13.34 billion, surpassing market expectations of $12.94 billion. This represents a 4% year-over-year increase, with the company's new immunology drugs, Skyrizi and Rinvoq, contributing significantly to this growth. Skyrizi, in particular, has shown remarkable performance, with its fourth-quarter sales exceeding those of Humira, the company's former flagship product.

Despite the decline in Humira sales due to biosimilar competition, AbbVie's overall performance remains robust. The company has also raised its full-year 2025 adjusted earnings per share (EPS) forecast to a range of $12.09 to $12.29, up from the previous estimate of $11.99. This adjustment reflects the strong sales of newer drugs and the company's strategic focus on innovation and growth.

Looking ahead, AbbVie is well-positioned to continue its growth trajectory. The company's pipeline includes several promising new drugs, such as Vylev for Parkinson's disease, which is expected to achieve peak sales of over $20 billion. Additionally, AbbVie's strategic investments in research and development are likely to yield further breakthroughs, ensuring sustained growth in the coming years.